Vera Therapeutics (VERA) Corporate presentation summary

Company overview

• San Francisco-based biotechnology firm with expertise in development and commercialization leadership.

• First commercial product is TRUTAKNA, a dual BAFF and APRIL inhibitor for autoimmune diseases.

• Holds exclusive global rights to TRUTAKNA, VT-109, and MAU868, targeting multiple autoimmune and kidney indications.

• Management team has a strong track record from leading biopharma companies.

• Maintains a robust financial position with $597M in cash and $425M available through a non-dilutive facility.

Product and pipeline highlights

• TRUTAKNA is FDA-accelerated approved for IgA nephropathy (IgAN), with Phase 3 eGFR results expected in Q3 2026.

• Pipeline includes additional autoimmune indications for TRUTAKNA, VT-109, and MAU868.

• Dual BAFF and APRIL inhibition offers precision B cell modulation, a potential paradigm shift in autoimmune therapy.

• TRUTAKNA is a rationally designed TACI-Fc fusion protein with high binding affinity for BAFF and APRIL.

Clinical data and efficacy

• ORIGIN Phase 2b showed long-term disease modification: 66% proteinuria reduction, 68% Gd-IgA1 reduction, 81% hematuria resolution, and eGFR stabilization.

• Phase 3 interim analysis demonstrated a 46% reduction in UPCR at 36 weeks versus placebo, consistent across subgroups.

• Gd-IgA1 reduction and hematuria resolution were significant, with odds ratio for hematuria resolution at 19.1.

• TRUTAKNA was generally well tolerated, with lower rates of serious adverse events than placebo and no deaths.